Straits Times Index
3,307.90 -6.15 (-0.19%) Nikkei
38,617.10 -329.83 (-0.85%) Hang Seng
19,195.60 -25.02 (-0.13%) FTSE 100
8,388.66 -27.79 (-0.33%) Bitcoin USD
69,947.43 -1,068.72 (-1.50%) CMC Crypto 200
1,517.35 -9.07 (-0.59%)
PMVP May 2024 2.500 put
| Previous close | 0.4700 |
| Open | 0.4700 |
| Bid | 0.0000 |
| Ask | 5.0000 |
| Strike | 2.50 |
| Expiry date | 2024-05-17 |
| Day's range | 0.4700 - 0.4700 |
| Contract range | N/A |
| Volume | |
| Open interest | 5 |
GlobeNewswirePMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights
First patient dosed and continued enrollment in Phase 2 portion of the PYNNACLE trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors Phase 1 data of rezatapopt in advanced ovarian cancer featured in late-breaking oral presentation at 2024 SGO Annual Meeting on Women’s Cancer Cash, cash equivalents, and marketable securities of $213.1 million as of March 31, 2024, providing expected cash runway to end of 2026 PRINCETON, N.J., May 09, 2024
Simply Wall St.PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
- GlobeNewswire
PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors
Rezatapopt is a first-in-class precision oncology investigational therapy for patients with advanced solid tumors with a TP53 Y220C mutation and KRAS wild-type (WT)First patient dosed in Phase 2 portion of the PYNNACLE trial which will assess rezatapopt as monotherapy in patients with TP53 Y220C and KRAS WT advanced solid tumors PRINCETON, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of sm
